Medical device company GlobalMed Technologies Company revealed on Friday a new partnership with DermaConcepts for the launch of the former's scientifically developed skin care product, GlycoAla in the US in the second quarter 2019.
Founded in 1994, DermaConcepts offers product lines which are world leaders in science-based and results- oriented skin care. In addition to exclusive distributorships, it offers industry leading education, training, and marketing support with an innovative business model for physicians, med spas, and wellness centres.
Under the terms of the agreement, DermaConcepts is now the official exclusive US distributor of GlycoAla.
According to the company, GlycoAla is the only photodynamic gel containing hyaluronic acid, a natural moisturiser, that utilises an advanced glycosphere nanoparticle delivery system for enhanced stability and skin absorption. It is activated by red light during a single session or three treatments spread over a 12-week period to help reduce the appearance of pore size, fine lines, and wrinkles and resulting in a brighter and more hydrated-looking skin tone.
Crossject advances paediatric development of ZEPIZURE Junior for epilepsy crisis management
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Tissue Regenix secures CE and UKCA certifications for OrthoPure XT
Terumo Corporation expands stroke portfolio in EMEA with SOFIA Flow 88 catheter launch
Crossject advances ZENEO manufacturing with scalable aseptic filling module ahead of product rollout
ZYLOX Unicorn Vascular Closure Device approved in Indonesia
Mindray unveils BeneVision V Series at Euroanaesthesia 2025, advancing precision monitoring
Unicon Pharma and VRR Life Sciences partner support digital transformation in life sciences
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software